By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


VentiRx Pharmaceuticals, Inc. 

1191 Second Avenue
Suite 1105
Seattle  Washington  98101  U.S.A.
Phone: 206-689-2259 Fax: n/a


Company News
VentiRx Pharmaceuticals, Inc. Announces The Completion Of Patient Enrollment In Randomized, Placebo-Controlled Phase 2 Trial Of VTX-2337 In Combination With Pegylated-Liposomal Doxorubicin In Platinum-Resistant Ovarian Cancer 4/17/2014 12:08:52 PM
VentiRx Pharmaceuticals, Inc. Presents Phase 1 Data On VTX-2337 At 2014 Multidisciplinary Head And Neck Cancer Symposia 2/20/2014 9:48:38 AM
VentiRx Pharmaceuticals, Inc. Initiates the ACTIVE8 Phase 2 Clinical Trial Evaluating VTX-2337 in Combination With Cetuximab and Chemotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 7/2/2013 9:55:06 AM
VentiRx Pharmaceuticals, Inc. Release: Preclinical and Phase 1 Data of VTX-2337 Presented at 2013 American Society of Clinical Oncology Annual Meeting Shows Early Activity in Ovarian Cancer 6/3/2013 8:24:43 AM
VentiRx Pharmaceuticals, Inc. Appoints James Kyle Bryan, M.D. as Chief Medical Officer 4/23/2013 7:38:54 AM
VentiRx Pharmaceuticals, Inc. Initiates Randomized, Placebo-Controlled, Phase 2 Trial of VTX-2337 in Patients With Recurrent or Persistent Ovarian Cancer 10/22/2012 9:49:19 AM
Celgene Corporation (CELG) Puts $35 Million Into VentiRx Pharmaceuticals, Inc., Gets Option to Buy Cancer Drugmaker 10/3/2012 6:45:23 AM
VentiRx Pharmaceuticals, Inc. Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer 1/23/2012 10:22:46 AM
VentiRx Pharmaceuticals, Inc. Concentrates on Cancer Development to Conserve Cash 9/14/2011 8:34:23 AM
VentiRx Pharmaceuticals, Inc. Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 10/7/2010 7:30:54 AM